FDA Approved: NILOTINIB — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for nilotinib from Cipla USA Inc., indicating an approved update to the drug's labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

SUPPL AP for NILOTINIB (NILOTINIB)